BCL-2 Inhibitor Venetoclax Induces Autophagy-Associated Cell Death, Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells

<h3>Introduction</h3><p dir="ltr">Venetoclax (VCX) is a selective BCL-2 inhibitor approved for the treatment of leukemia and lymphoma. However, the mechanisms of anti-cancer effect of VCX either as a monotherapy or in combination with other chemotherapeutic agents against...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Ali Alhoshani (3720718) (author)
مؤلفون آخرون:	Fahad O Alatawi (16555622) (author), Fawaz E Al-Anazi (16555625) (author), Ibraheem M. Attafi (14151735) (author), Asad Zeidan (8879705) (author), Abdelali Agouni (181926) (author), Heba M El Gamal (16555631) (author), Licia S Shamoon (16555641) (author), Sarah Khalaf (16555642) (author), Hesham M Korashy (16555645) (author)
منشور في:	2020
الموضوعات:	Biomedical and clinical sciences Oncology and carcinogenesis Pharmacology and pharmaceutical sciences venetoclax MDA-MB-231 cells breast cancer apoptosis BCL-2 cell cycle autophagy
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

BCL-2 Inhibitor Venetoclax Induces Autophagy-Associated Cell Death, Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells

مواد مشابهة